Sector Gamma As Increases Position in Gilead Sciences (GILD); Hahn Capital Management Holding in Laboratory Corp. Of America Holdings (LH) Trimmed as Share Price Declined

December 17, 2017 - By Kurt Siggers

Sector Gamma As increased its stake in Gilead Sciences Inc (GILD) by 22.27% based on its latest 2017Q2 regulatory filing with the SEC. Sector Gamma As bought 99,900 shares as the company’s stock declined 8.05% while stock markets rallied. The institutional investor held 548,390 shares of the health care company at the end of 2017Q2, valued at $38.82 million, up from 448,490 at the end of the previous reported quarter. Sector Gamma As who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $97.92B market cap company. The stock decreased 1.45% or $1.1 during the last trading session, reaching $74.96. About 3.79 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since December 17, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Hahn Capital Management Llc decreased its stake in Laboratory Corp. Of America Holdings (LH) by 10.72% based on its latest 2017Q2 regulatory filing with the SEC. Hahn Capital Management Llc sold 23,290 shares as the company’s stock declined 0.17% while stock markets rallied. The institutional investor held 193,907 shares of the medical specialities company at the end of 2017Q2, valued at $29.89 billion, down from 217,197 at the end of the previous reported quarter. Hahn Capital Management Llc who had been investing in Laboratory Corp. Of America Holdings for a number of months, seems to be less bullish one the $15.92 billion market cap company. The stock increased 0.08% or $0.13 during the last trading session, reaching $156.39. About 144,322 shares traded. Laboratory Corporation of America Holdings (NYSE:LH) has risen 10.51% since December 17, 2016 and is uptrending. It has underperformed by 6.19% the S&P500.

Among 18 analysts covering Laboratory Corp (NYSE:LH), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Laboratory Corp had 46 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Craig Hallum with “Buy” on Thursday, October 26. The rating was maintained by Jefferies on Friday, June 9 with “Hold”. As per Monday, February 6, the company rating was downgraded by Robert W. Baird. Piper Jaffray maintained the stock with “Buy” rating in Monday, October 16 report. The rating was maintained by Jefferies on Thursday, October 19 with “Hold”. The stock of Laboratory Corporation of America Holdings (NYSE:LH) has “Neutral” rating given on Friday, February 17 by Mizuho. Wells Fargo upgraded Laboratory Corporation of America Holdings (NYSE:LH) rating on Thursday, October 12. Wells Fargo has “Buy” rating and $175.0 target. Robert W. Baird maintained Laboratory Corporation of America Holdings (NYSE:LH) on Sunday, October 15 with “Hold” rating. Barclays Capital maintained the shares of LH in report on Tuesday, April 26 with “Overweight” rating. The firm earned “Overweight” rating on Thursday, August 10 by Morgan Stanley.

Hahn Capital Management Llc, which manages about $963.10 million US Long portfolio, upped its stake in Mid (NYSE:MAA) by 43,651 shares to 273,802 shares, valued at $28.85 billion in 2017Q2, according to the filing.

Since August 1, 2017, it had 0 buys, and 7 insider sales for $14.75 million activity. Another trade for 3,100 shares valued at $486,338 was made by Williams R Sanders on Friday, August 11. $7.01M worth of Laboratory Corporation of America Holdings (NYSE:LH) was sold by KING DAVID P. The insider Uthgenannt Lisa J sold 5,000 shares worth $800,000. On Monday, October 30 Gilliland Dwight Gary sold $149,068 worth of Laboratory Corporation of America Holdings (NYSE:LH) or 971 shares. $459,739 worth of Laboratory Corporation of America Holdings (NYSE:LH) shares were sold by Dodson Edward T. EISENBERG GLENN A sold $951,672 worth of stock or 5,968 shares.

Investors sentiment increased to 1.06 in 2017 Q2. Its up 0.05, from 1.01 in 2017Q1. It increased, as 44 investors sold LH shares while 207 reduced holdings. 66 funds opened positions while 199 raised stakes. 93.49 million shares or 2.05% more from 91.61 million shares in 2017Q1 were reported. Jacobs And Ca, a California-based fund reported 20,614 shares. Klingenstein Fields Limited Liability holds 1.33% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH) for 219,879 shares. Liberty Mutual Gru Asset Management holds 6,086 shares. Citadel Llc reported 431,411 shares. Voya Investment Mgmt Limited accumulated 280,616 shares or 0.1% of the stock. Hartford Investment Management invested in 22,137 shares. Royal Bankshares Of Canada, a Ontario – Canada-based fund reported 217,128 shares. Duncker Streett & holds 0.21% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH) for 4,353 shares. Rothschild Asset holds 3,203 shares or 0.01% of its portfolio. Waddell & Reed Fincl Inc stated it has 0.32% in Laboratory Corporation of America Holdings (NYSE:LH). 237 were reported by Cwm Ltd Limited Liability Company. California State Teachers Retirement Sys reported 193,642 shares. Da Davidson owns 7,186 shares for 0.03% of their portfolio. Mufg Americas invested 0.09% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH). Security Financial Bank Of Sioux City Iowa Ia has invested 2.1% of its portfolio in Laboratory Corporation of America Holdings (NYSE:LH).

Analysts await Laboratory Corporation of America Holdings (NYSE:LH) to report earnings on February, 15. They expect $2.41 EPS, up 12.09% or $0.26 from last year’s $2.15 per share. LH’s profit will be $245.35 million for 16.22 P/E if the $2.41 EPS becomes a reality. After $2.46 actual EPS reported by Laboratory Corporation of America Holdings for the previous quarter, Wall Street now forecasts -2.03% negative EPS growth.

Sector Gamma As, which manages about $687.83 million US Long portfolio, decreased its stake in Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) by 107,681 shares to 1.83M shares, valued at $34.61M in 2017Q2, according to the filing. It also reduced its holding in Lifepoint Health Inc (NASDAQ:LPNT) by 15,000 shares in the quarter, leaving it with 149,714 shares, and cut its stake in Anthem Inc (NYSE:ANTM).

Investors sentiment increased to 0.93 in Q2 2017. Its up 0.02, from 0.91 in 2017Q1. It improved, as 78 investors sold GILD shares while 538 reduced holdings. 110 funds opened positions while 462 raised stakes. 938.32 million shares or 0.11% more from 937.32 million shares in 2017Q1 were reported. Td Cap Management Ltd Liability invested in 360 shares. Tci Wealth Advsrs Inc accumulated 1,261 shares. Century holds 4.10 million shares or 0.3% of its portfolio. Lowe Brockenbrough & Company Incorporated invested in 19,395 shares. St Johns Mgmt Co Limited Liability holds 0.27% or 5,036 shares in its portfolio. The Massachusetts-based Boston Common Asset Mgmt has invested 0.54% in Gilead Sciences, Inc. (NASDAQ:GILD). Huntington Natl Bank invested in 211,119 shares or 0.26% of the stock. Omers Administration Corp reported 23,300 shares stake. Aperio Ltd Liability Corporation invested 0.34% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Westwood Hldgs Group Inc Inc has 399 shares for 0% of their portfolio. Boston Family Office Lc holds 118,459 shares. Cognios Capital Ltd Liability Corp holds 48,210 shares. Holowesko Ptnrs Ltd holds 5.76% in Gilead Sciences, Inc. (NASDAQ:GILD) or 1.21 million shares. 55,790 are owned by Assets Investment Mgmt. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Inv Management stated it has 0.17% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD).

Since August 1, 2017, it had 0 insider buys, and 9 insider sales for $36.34 million activity. MARTIN JOHN C sold $6.09 million worth of stock or 73,333 shares. $4.99 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Meyers James R on Thursday, August 31. Shares for $4.40M were sold by Washington Robin L on Thursday, September 7.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 107 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Wednesday, October 4 by Oppenheimer. The firm earned “Strong Buy” rating on Thursday, September 10 by Jyske Bank. As per Friday, October 6, the company rating was maintained by Morgan Stanley. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Monday, August 28 by Credit Suisse. The firm earned “Market Perform” rating on Thursday, October 19 by Leerink Swann. The stock has “Buy” rating by Jefferies on Monday, June 12. The rating was maintained by BMO Capital Markets with “Hold” on Monday, August 28. Oppenheimer maintained it with “Outperform” rating and $120 target in Wednesday, July 29 report. Berenberg initiated it with “Buy” rating and $112 target in Monday, September 12 report. The rating was maintained by Piper Jaffray on Wednesday, February 3 with “Overweight”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: